ADMA

AI Memo

ADMA Biologics

As of 2026-10-25/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-25 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

ASCENIV real-world evidence at ACAAI • 2026-11-30

Base target: $12 / p=1% prob

Biggest risk

Total second-quarter revenue grew only 2% despite ASCENIV's 24% growth. Competitive pricing pressure on BIVIGAM could continue to offset ASCENIV gains, while the real-world evidence may not translate into faster sales. [#SEC-8K-2026-08-05]

Invalidation

Break below $8 or thesis failure.

What would change my mind?

ASCENIV adoption and favorable product mix sustain growth and profitability despite standard immune-globulin competition. ADMA reiterated its 2026 revenue, adjusted-net-income and adjusted-EBITDA ranges. [#SEC-8K-2026-08-05]

Research note

Recommendation

—

Confidence

medium

As of

2026-10-25

Base target

$12

p=1%

Bull target

$15

p=0%

Bear target

p=0%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

ASCENIV adoption and favorable product mix sustain growth and profitability despite standard immune-globulin competition.
ADMA reiterated its 2026 revenue, adjusted-net-income and adjusted-EBITDA ranges.
[#SEC-8K-2026-08-05]

BearKey bullets

Heavy reliance on ASCENIV growth leaves results sensitive to any slowdown in adoption or utilization.
[#SEC-8K-2026-08-05]
Persistent competition and pricing pressure in the standard U.S.

WatchKey bullets

ASCENIV real-world evidence at ACAAI

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $12 (p=1%)

Target spread vs base: +25% / -37%

Scenario probabilities

Bull Target: $15 (p=0%)Base Target: $12 (p=1%)Bear Target: $8 (p=0%)

Commentary

Company-reported ASCENIV growth and reiterated guidance are constructive, but the outlook was not raised. A September 4 Zacks recap reported shares down about 4.8% in the month after earnings; this is not an immediate post-release reaction. Current analyst revisions, options skew, short interest, employee ratings and social sentiment were not verified. Zero-valued sentiment fields denote unavailable data, not neutral readings.

As of 2026-10-25 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

ASCENIV adoption and favorable product mix sustain growth and profitability despite standard immune-globulin competition.
ADMA reiterated its 2026 revenue, adjusted-net-income and adjusted-EBITDA ranges.
[#SEC-8K-2026-08-05]

Scenarios

Bull Target (Scenario probability)

$15 / p=0% prob

Base Target (Scenario probability)

$12 / p=1% prob

Bear Target (Scenario probability)

$8 / p=0% prob

Analysis 2026-10-25 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-30
ASCENIV real-world evidence at ACAAI
ADMA submitted an abstract covering 127 ASCENIV-treated patients for the November 2026 ACAAI meeting. Disclosure could strengthen the product's commercial evidence base, but incremental sales remain unproven. November 30 is a monitoring date, not a confirmed presentation date. [#SEC-8K-2026-08-05]
Prob 65.00% • Move 5.00% • Priced-in 25.00%
EVENT2026-12-31
ASCENIV growth against reiterated 2026 guidance
Second-quarter ASCENIV revenue rose 24% year over year to $102.9 million, while total revenue rose 2% to $124.4 million. ADMA reiterated 2026 revenue guidance of $530 million–$560 million. The test is whether ASCENIV uptake continues to offset pressure in the standard immune-globulin market; December 31 is a fiscal-year monitoring date, not an announced results date. [#SEC-8K-2026-08-05] [#8-K-2026-08-05]
Prob 65.00% • Move 8.00% • Priced-in 45.00%

Risks

Heavy reliance on ASCENIV growth leaves results sensitive to any slowdown in adoption or utilization. [#SEC-8K-2026-08-05]
Persistent competition and pricing pressure in the standard U.S. immune-globulin market are explicitly reflected in ADMA's 2026 outlook. [#SEC-8K-2026-08-05]
Submitted real-world evidence is not proof of incremental commercial uptake or a regulatory milestone. [#SEC-8K-2026-08-05]

Peers

Symbol	Summary
CSL	CSL provides an immunoglobulin demand and manufacturing reference, but its greater scale and diversification make it an imperfect valuation peer.
GRFS	Grifols is a closer plasma-derived immunoglobulin operating reference than the packet's market-cap matches, though its broader business limits valuation comparability.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-25

Loading AI feed…

Symbol

Summary

CSL

CSL provides an immunoglobulin demand and manufacturing reference, but its greater scale and diversification make it an imperfect valuation peer.

GRFS

Grifols is a closer plasma-derived immunoglobulin operating reference than the packet's market-cap matches, though its broader business limits valuation comparability.